Immune thrombocytopenia (ITP) trials in China

In China 67 Also abroad 118

67 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 2Not yet taking people in China
Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy
Where
Beijing
Age
18 years to 80 years
People
28
Run by
Peking Union Medical College Hospital
See details and how to joinNCT07400250
Phase 2Taking people
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
Where
Tianjin
Age
18 years and over
People
20
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07362199
Phase 2Taking people
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
Where
Tianjin
Age
6 years to 18 years
People
122
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07362238
Phase 2Taking people
A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)
Where
Jinan
Age
18 years and over
People
60
Run by
Dizal Pharmaceuticals
See details and how to joinNCT07294365
No phaseNot yet taking people in China
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
Where
Tianjin
Age
18 years to 65 years
People
24
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07212322
Phase 1/2Taking people
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
Where
Changzhi, Tianjin, Zhengzhou
Age
18 years and over
People
158
Run by
Keymed Biosciences Co.Ltd
See details and how to joinNCT07175493
No phaseTaking people
Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia
Where
Suzhou
Age
14 years and over
People
30
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07206823
Phase 2Taking people
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
Where
Tianjin
Age
6 years to 17 years
People
60
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06168851
Early phase 1Taking people
Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)
Where
Wuhan
Age
18 years and over
People
6
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06519565
Phase 1/2Not yet taking people in China
An Exploratory Study of Golidocitinib in Adult Patients With ITP
Where
Beijing
Age
18 years to 80 years
People
138
Run by
Peking University People's Hospital
See details and how to joinNCT07196163
Phase 4Not yet taking people in China
Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP
Where
Wuhan
Age
12 years to 75 years
People
150
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07189910
Early phase 1Taking people
Safety Study of CC312 in Autoimmune Disease Patients
Where
Tianjin
Age
18 years and over
People
18
Run by
CytoCares Inc
See details and how to joinNCT06888960
Phase 2Taking people
The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)
Where
Beijing
Age
18 years and over
People
132
Run by
Peking University People's Hospital
See details and how to joinNCT07065968
No phaseTaking people
Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia
Where
Changsha
Age
18 years and over
People
18
Run by
Anhui Provincial Hospital
See details and how to joinNCT06973356
Phase 1Taking people
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
Where
Beijing
Age
18 years to 70 years
People
12
Run by
Juventas Cell Therapy Ltd.
See details and how to joinNCT06826430
Phase 1/2Taking people
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
Where
Tianjin
Age
18 years and over
People
20
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06776510
Phase 2Taking people
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
Where
Tianjin
Age
6 years to 18 years
People
30
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06838962
Phase 2Not yet taking people in China
A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults
Where
Anyang, Baoding, Beijing, Changchun, Changsha, Changzhi, Chengde, Chongqing, Ganzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Linyi, Nanchang, Nanjing, Nanning, Nantong, Nanyang, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Ürümqi, Wuhan, Wuhu, Xi'an, Xi’an, Xining, Yantai, Zhanjiang, Zhengzhou
Age
18 years and over
People
320
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07083739
No phaseNot yet taking people in China
Longitudinal Observational Study on Immune Thrombocytopenia
Where
Beijing
People
2,000
Run by
Peking University People's Hospital
See details and how to joinNCT07068425
Phase 2Not yet taking people in China
The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
Where
Beijing
Age
18 years to 70 years
People
132
Run by
Peking University People's Hospital
See details and how to joinNCT07064889
Phase 2Taking people
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
Where
Tianjin
Age
60 years and over
People
30
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07063199
Phase 2Not yet taking people in China
Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP
Where
Beijing
Age
18 years to 70 years
People
120
Run by
Peking University People's Hospital
See details and how to joinNCT07057778
Phase 1/2Taking people
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
Where
Jinan, Kunming, Nanchang, Tangshan, Tianjin, Zhengzhou
Age
18 years to 65 years
People
75
Run by
CASI pharmaceuticals, Inc.
See details and how to joinNCT07017725
Phase 2Taking people
Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial
Where
Tianjin
Age
18 years to 75 years
People
129
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06992128
Phase 3Taking people
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
Where
Anyang, Baoding, Beijing, Changchun, Changsha, Changzhi, Chengde, Chongqing, Ganzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Linyi, Nanchang, Nanjing, Nanning, Nantong, Nanyang, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Ürümqi, Wuhan, Wuhu, Xi'an, Xi’an, Xining, Xuchang, Yangzhou, Yantai, Zhanjiang, Zhengzhou
Age
18 years to 75 years
People
199
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT06900920